Quick Facts

• Primary Therapeutic Domain: Supports the management of iron deficiency anemia.
• Specific Uses: Addresses low iron stores and supports healthy red blood cell production.
• Benefit Contexts: Indicated to manage iron deficiency during periods of increased need, such as pregnancy and lactation.

---

Orofer is an authorized treatment option intended to address iron deficiency anemia. This condition is characterized by low iron levels that may compromise the body's ability to produce adequate red blood cells.

The core function of the product is to help restore depleted iron stores. This supportive mechanism facilitates the formation of red blood cells, which are crucial for oxygen transport throughout the body. By supporting these vital functions, the medication may help to manage symptoms associated with low iron levels, such as fatigue and reduced energy. The use of this product is generally considered a foundational approach for restoring iron balance when nutritional intake is insufficient or iron requirements are elevated.

In specific patient populations, the medication is also indicated for the prevention of iron deficiency states, particularly during pregnancy, where the body's need for iron is significantly increased to support fetal development and maternal blood volume. It is an established first-line intervention for managing iron deficiency in most cases.

Eligibility Profile: Who Can and Cannot Use Orofer?

This section outlines the official eligibility and non-eligibility criteria for Orofer (Iron(III)-hydroxide polymaltose complex and Folic Acid), strictly based on governmental regulatory documentation.

---

Contraindications (Must Not Use)

Orofer is contraindicated in patients with the following conditions, as administering supplemental iron would be inappropriate or harmful:

• Iron Overload: Conditions such as hemochromatosis or hemosiderosis.
• Disturbances in Iron Utilization: Including sideroblastic anemia, thalassemia, and lead anemia.
• Non-Iron Deficiency Anemia: Any anemia not caused by iron deficiency, such as hemolytic anemia or megaloblastic anemia due to Vitamin B12 deficiency.
• Hypersensitivity: Known allergy to the active ingredients or excipients.

Conditional Use and Restrictions

• Age Restriction: The medicine is not recommended for children and adolescents aged 12 years and younger due to insufficient data for the iron complex component in this age group.
• Pregnancy and Lactation: Use is generally allowed but requires consultation with a medical doctor as a precautionary measure.
• Other Restrictions: Patients receiving repeated blood transfusions or those whose anemia is caused by underlying infections or tumors must use the medicine only after careful medical evaluation.

Interactions with other medicines and products

Orofer, containing Iron, Folic Acid, and Cyanocobalamin, has officially documented interaction patterns primarily centered on the Iron component's effect on gastrointestinal absorption. This pharmacokinetic mechanism, involving chelation, leads to reduced plasma exposure of both Iron and certain co-administered medicinal products.

Documented Interaction Classes

The regulatory profile identifies two main areas of interaction:

• Absorption Interference: Iron forms complexes with various drugs, notably Tetracycline and Quinolone antibiotics, Bisphosphonates, and Levothyroxine. This binding reduces the oral bioavailability of these agents and requires mandatory separation of administration time.
• Pharmacodynamic/Metabolic Effects: Folic Acid is associated with interactions that can modulate the effects or plasma concentrations of specific agents, including certain antiepileptic drugs (such as Phenytoin) and antimetabolites like Raltitrexed, as noted in official labels.

Administration Restrictions

To mitigate the effect of absorption interference, regulatory documents establish mandatory timing separation rules:

• Two to Three Hours Separation: Required for co-administration with Tetracycline antibiotics.
• Two Hours Separation: Required for co-administration with Quinolone antibiotics, Levothyroxine, Penicillamine, and Antacids (containing Aluminum, Magnesium, or Calcium).

Drug-Food and Supplement Interactions

The absorption of Iron is officially documented as being reduced by specific dietary components, including high-phytate foods, coffee, tea, and calcium-containing dairy products. Mineral supplements containing Zinc or Calcium also interfere with Iron absorption through competition or chelation.

How Orofer Works

This section details the drug's action at the molecular and cellular level, focusing on the biological targets and pathways it influences to support core metabolic requirements.

---

1. Oxygen Transport Substrate Replenishment

This mechanism centers on providing the essential element, Ferrous iron (Fe^2+), which acts as a fundamental substrate for the heme synthesis pathway. This replenishment is critical for the formation of hemoglobin, which contributes to the synthesis of the metalloprotein component required for oxygen transport within the circulatory system.

---

2. Erythrocyte Production Pathway Support

Orofer provides Folic acid, a crucial cofactor involved in metabolic cascades that are necessary for the synthesis of DNA and RNA. This targeted action is essential for the continuous, high-rate cellular division and nuclear maturation that occurs during erythropoiesis (red blood cell production) within the bone marrow.

---

3. Optimized Gastrointestinal Bioavailability Cascade

The specific Ferrous ascorbate formulation acts to influence the absorption cascade by using ascorbate (Vitamin C) as a chelating and reducing agent. This mechanism ensures that iron is maintained in the absorbable Ferrous (Fe^2+) state within the intestinal lumen, thereby supporting systemic uptake for subsequent incorporation into plasma and tissue binding proteins.

How Orofer Is Used: Administration Guidelines

This section details the usage and administration for Orofer (a combination haematinic). These guidelines describe the standardized approach to its intake, timing, and duration.

Administration and Dosage

Orofer is used for oral administration as a solid form (capsule or tablet). The following usage patterns are recognized:

Usage Purpose	Standard Dose	Frequency
Treatment of Deficiency	1 Capsule/Tablet	Twice Daily (b.i.d.)
Prevention/Prophylaxis	1 Capsule/Tablet	Once Daily (q.d.)

All use must be managed under medical supervision.

Key Instructions and Duration of Use

• Intake Method: The capsule or tablet is to be swallowed whole with water. It is not to be crushed, chewed, or broken.
• Timing: To aid tolerability, the medicine is often taken with or immediately after a meal.
• Population Use: The product is used in adults and adolescents, and is indicated for use during pregnancy and lactation as a supplement.
• Treatment Duration: The course of therapy is time-dependent. Normalization of blood hemoglobin values typically requires approximately three to five months. Following this, therapy is often continued for at least one additional month to replenish the body's iron stores.

Research evidence / Overview of Studies for Orofer

The clinical evaluation of Orofer, a combination of iron, folic acid, and cyanocobalamin (Vitamin B12), research examines the components' role in addressing nutritional deficits associated with anemia. The evidence base is derived from Randomized Controlled Trials (RCTs) and Systematic Reviews, exploring measurements of hematological status, often in populations facing high nutritional need.

Evidence for Treating Iron Deficiency Anemia

Researchers have used short-term and intermediate-term RCTs to explore the effects of oral iron and vitamin combinations in adults and women of reproductive age diagnosed with iron deficiency anemia. Study endpoints monitored hematological markers, such as the concentration of hemoglobin (Hb) and levels of serum ferritin, over periods typically lasting several months.

Studies reported that the use of oral iron and the accompanying B-vitamins was associated with changes measured in Hb concentration and shifts in ferritin levels. The research provides context for patterns related to these biochemical outcomes.

Evidence for Supplementation During Pregnancy

A substantial body of research, including large-scale cohort studies and systematic reviews, has explored the use of these components for addressing nutritional requirements during pregnancy, a time of significantly increased nutritional demand. This research primarily included pregnant women and focused on outcomes related to maternal blood status (such as anemia prevalence and Hb levels).

Public health studies reported measurements that showed patterns related to a lower prevalence of maternal anemia at term when compared to control groups. The inclusion of Folic Acid, in particular, was studied in research examining certain fetal developmental outcomes.

Evidence Gaps and Uncertainty

Scientific literature notes several areas where the evidence landscape remains incomplete or uncertain. Comparative evidence is lacking for many research scenarios. Specifically, the observed effect of adding the Vitamin B12 component to a dual Iron/Folic Acid supplement in groups without confirmed low B12 levels is not fully characterized across all populations. Follow-up durations were limited in many studies, meaning certainty remains low regarding sustained change over time.

Key Studies & References

1. WHO Model List of Essential Medicines (Ferrous salt + folic acid entry)
2. Cyanocobalamin (Vitamin B12) - StatPearls [StatPearls - NCBI Bookshelf]

Common questions about Orofer (FAQ)

Q: What is the main ingredient in Orofer and what is it used for?

A: Orofer contains ferric hydroxide polymaltose complex (IPC), which is a type of iron supplement. According to regulatory documents, its primary use is for the management of various types of iron-deficiency anemia, a condition characterized by low levels of healthy red blood cells.

---

Q: Can I take Orofer with food or drinks?

A: Regulatory documents mention that taking the product with or immediately after food may help reduce the incidence of digestive side effects. This is a common practice with oral iron supplements. Detailed instructions on administration, including information about food, are typically found in the full 'How to use Orofer' section of the product information.

---

Q: How should I store Orofer?

A: Regulatory information indicates that Orofer should be stored at room temperature, which is below 25°C. Official documentation specifies that the medicine should be kept in a dry place, protected from light. As with all medicines, it must be stored safely out of the sight and reach of children.

---

Q: Is Orofer suitable for use during pregnancy and while breastfeeding?

A: Studies and official information indicate that Orofer is generally considered suitable for use during pregnancy and while breastfeeding when iron supplementation is required. Decisions regarding treatment in these circumstances are made by a healthcare professional, who assesses the individual's need, benefits, and risks.

---

Q: Does Orofer need to be stopped before an endoscopy?

A: Regulatory documents state that iron preparations, including Orofer, are typically discontinued for a few days prior to an endoscopy. This is due to the potential for iron to cause staining in the digestive tract, which might interfere with the diagnostic procedure. Consult the product label for specific guidance on preparing for tests.

---

Q: What is the acceptable shelf-life or expiry of Orofer?

A: Regulatory documents state that the acceptable shelf-life for Orofer is 36 months from the date of manufacture. This information is based on the period it is expected to remain stable and effective when stored according to the recommended conditions specified on the packaging.

The storage and disposal instructions for Orofer (Iron Sucrose or Ferric Carboxymaltose injection) must be strictly adhered to and will be provided by your healthcare professional or pharmacist.

Storage Guidelines

Product Form	Storage Temperature	Key Precautions
Injection	Typically store below 25°C or 30°C. Do not freeze.	Keep in the original packaging to protect from light. Use immediately after opening or dilution.
Oral Tablet	Store at room temperature (around 25°C) in a dry place.	Protect from light and moisture. Keep out of the reach of children and pets.

Disposal

Any unused or expired medicine must be disposed of in a manner that protects public health and the environment, following local requirements. Do not flush any form of this medication down the toilet or pour it into a drain unless instructed to do so. In the case of injections, special disposal procedures for medical sharps should be followed.